Ivan Wasserman’s practice is focused on matters involving the marketing of foods, dietary supplements, cosmetics, drugs, and medical devices. With extensive experience advising clients on the advertising and labeling of products such as these, which are subject to overlapping jurisdiction of the Food and Drug Administration (FDA) and the Federal Trade Commission (FTC), he helps his clients develop creative approaches to meeting marketing objectives while staying within the constraints of applicable regulatory frameworks. In addition to working with products regulated by the FDA, Mr. Wasserman has extensive experience advising clients on the regulation of consumer products by the Consumer Product Safety Commission (CPSC).
FDA: As an FDA lawyer, Mr. Wasserman’s practice includes:
Advertising and labeling reviews
Ingredient reviews and product formulation issues
Responding to FDA warning letters
Responding to import detentions and product seizures
Adverse event reporting and product recalls
Preparing 510(k) premarket notifications for medical devices
Preparing New Dietary Ingredient (NDI) notifications for supplements
Advertising: Mr. Wasserman is an experienced advertising lawyer who regularly reviews advertising campaigns, including websites, for regulatory compliance. When additional data is necessary to support desired claims, Mr. Wasserman works with the company to develop the needed substantiation. In addition to federal and state agencies, his practice includes representing clients in proceedings before the National Advertising Division (NAD) of the Council of Better Business Bureaus (CBBB) and the Electronic Retailing Self-Regulation Program (ERSP).
CPSC: Mr. Wasserman is an experienced CPSC lawyer who draws upon his strong background in consumer product safety issues to help clients comply with the CPSC’s labeling and reporting requirements. When a corrective action is necessary, he helps clients conduct effective product recalls and minimize adverse publicity. Also, he is experienced in handling CPSC investigations into whether companies complied with the reporting requirements of Section 15(b) of the Consumer Product Safety Act (CPSA).